Calidi Biotherapeutics ( (CLDI) ) has shared an announcement.
On March 10, 2025, Calidi Biotherapeutics announced promising preclinical results for its RTNova platform, which successfully delivered transient gene therapy payloads to tumors. The platform addresses challenges in treating advanced metastatic cancers by using a vaccinia virus strain enveloped with a human cell membrane to target distant tumors. This innovation has shown efficacy in altering the tumor microenvironment and eradicating certain tumors in preclinical models, potentially revolutionizing cancer treatment and opening opportunities for partnerships.
More about Calidi Biotherapeutics
Calidi Biotherapeutics is a clinical-stage biotechnology company based in San Diego, specializing in immuno-oncology. The company focuses on developing targeted antitumor virotherapies using proprietary stem cell-based platforms. These platforms are designed to deliver oncolytic viruses for treating various oncology indications, including high-grade gliomas and solid tumors, with an emphasis on enhancing efficacy and patient safety.
YTD Price Performance: -27.97%
Average Trading Volume: 1,618,894
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $22.04M
Find detailed analytics on CLDI stock on TipRanks’ Stock Analysis page.